---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-019536"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:49:04.384833+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share

## Summary
- 5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.
- Underwriters have 30-day option to purchase up to 884,615 additional shares.
- Proceeds to fund BGE-102, NLRP3, and APJ programs, plus working capital and debt reduction.
- Goldman Sachs, Piper Sandler, and Citigroup are joint book-running managers.
- Offering expected to close on January 23, 2026, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-26-019536
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/bioa-20260121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-019536
- JSON: https://secwatch.observer/filing/0001193125-26-019536.json
- Plain text: https://secwatch.observer/filing/0001193125-26-019536.txt

## Key facts
- Material Agreements
  BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters
  - Value: $107.6 million
  - Effective: 2026-01-21
  source text: On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.